株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

自己免疫疾患の米国市場:2015年〜2019年

Autoimmune Diseases Market in the US 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 335106
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
自己免疫疾患の米国市場:2015年〜2019年 Autoimmune Diseases Market in the US 2015-2019
出版日: 2015年07月08日 ページ情報: 英文 95 Pages
概要

米国の自己免疫疾患市場は、2014年〜2019年のCAGRで、6.17%の成長が見込まれています。

当レポートでは、米国の自己免疫疾患市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 疾患の概要

  • 疾患について
  • 疫学
  • 病因
  • 症状
  • 診断
  • 疾患管理
  • 生活の質 (QoL)

第7章 市場情勢

  • 市場概要
  • 市場規模と予測

第8章 パイプラインポートフォリオ

  • パイプライン情勢:クローン病
  • パイプライン情勢:多発性硬化症
  • パイプライン情勢:全身性エリテマトーデス
  • ファイブフォース分析

第9章 市場区分:疾患の種類別

  • 強直性脊椎炎
  • クローン病
  • 多発性硬化症
  • 乾癬
  • 関節リウマチ
  • 全身性エリテマトーデス

第10章 市場区分:分子の種類別

  • 小分子
  • 生物製剤

第11章 市場区分:投与経路別

  • 非経口経路
  • 経口経路

第12章 米国の強直性脊椎炎市場

  • 市場規模と予測

第13章 米国のクローン病市場

  • 市場規模と予測

第14章 米国の多発性硬化症市場

  • 市場規模と予測

第15章 米国の関節リウマチ市場

  • 市場規模と予測

第16章 米国の乾癬市場

  • 市場規模と予測

第17章 米国の全身性エリテマトーデス市場

  • 市場規模と予測

第18章 購入基準

第19章 市場成長促進要因

第20章 成長促進要因とその影響

第21章 市場の課題

第22章 成長促進要因と課題の影響

第23章 市場動向

第24章 動向とその影響

第25章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他・将来有望なベンダー

第26章 主要ベンダー分析

  • AbbVie
  • Amgen
  • Biogen
  • F. Hoffmann-La Roche
  • Janssen Pharmaceuticals

第27章 関連レポート

図表

目次
Product Code: IRTNTR6443

About Autoimmune Diseases

Autoimmune diseases are caused by aggravation of the immune system. Autoimmune diseases can last for months or even years. Autoimmune reactions occur when the immune system produces autoantibodies that attack and destroy healthy tissues in the body rather than infectious agents. These autoantibodies cause inflammation, pain, and organ damage. It is also known as a disease of flare-ups and remissions, and can range from mild to life-threatening in severity. No cure exists for autoimmune diseases yet. Autoimmune diseases can affect the cardiovascular system, brain, nerves, musculoskeletal system, skin, lungs, kidneys, glands, or joints. They are caused by genetic, infectious, and environmental factors. According to NIH, there are more than 80 clinically different autoimmune diseases. Some of the common types of autoimmune diseases are ankylosing spondylitis, Crohn's disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and psoriasis.

Technavio's analysts forecast the autoimmune diseases market in the US to grow at a CAGR of 6.17% over the period 2014-2019.

Covered in this Report

The report includes the present scenario and the growth prospects of the autoimmune diseases market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of autoimmune diseases.

Technavio's report, Autoimmune Diseases Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast for individual diseases as well as the overall market and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key Vendors

  • AbbVie
  • Amgen
  • Biogen
  • F. Hoffmann-La Roche
  • Janssen Pharmaceuticals

Other Prominent Vendors

  • AB Science
  • Acorda Therapeutics
  • aTyr Pharma
  • Baxter
  • Celgene
  • Celltrion
  • Coherus BioSciences
  • Daiichi Sankyo
  • Eli Lilly
  • GlaxoSmithKline
  • HGS
  • Hospira
  • Idera
  • Immunomedics
  • ImmuPharma
  • Invion
  • Latona Life Sciences
  • MedImmune
  • Merck
  • Novartis
  • Opexa Therapeutics
  • Principia
  • Reata Pharmaceuticals
  • Regeneron
  • Sanofi
  • Sobi
  • Takeda
  • Teva
  • UCB
  • Vaccinex
  • Vitae Pharmaceuticals

Key Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Key Market Challenge

  • High Cost of Therapy
  • For a full, detailed list, view our report

Key Market Trend

  • Increase in Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Epidemiology
  • 06.3. Etiology
  • 06.4. Symptoms
  • 06.5. Diagnosis
    • 06.5.1. Medical History
    • 06.5.2. Laboratory examination
  • 06.6. Disease Management
  • 06.7. Quality of Life

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast

08. Pipeline Portfolio

  • 08.1. Pipeline Landscape: Crohn's Disease
  • 08.2. Pipeline Landscape: Multiple Sclerosis
  • 08.3. Pipeline Landscape: Systemic Lupus Erythematosus
  • 08.5. Five Forces Analysis

09. Market Segmentation by Type of Diseases

  • 09.1. Ankylosing Spondylitis
  • 09.2. Crohn's Disease
  • 09.3. Multiple Sclerosis
  • 09.4. Psoriasis
  • 09.5. Rheumatoid Arthritis
  • 09.6. Systemic Lupus Erythematosus

10. Market Segmentation by Type of Molecules

    • 10.1.1. Small Molecules
    • 10.1.2. Biologics

11. Market Segmentation by Route of Administration

    • 11.1.1. Parenteral Route
    • 11.1.2. Oral Route

12. Ankylosing Spondylitis Market in the US

  • 12.1. Market Size and Forecast

13. Crohn's Disease Market in the US

  • 13.1. Market Size and Forecast

14. Multiple Sclerosis Market in the US

  • 14.1. Market Size and Forecast

15. Rheumatoid Arthritis Market in the US

  • 15.1. Market Size and Forecast

16. Psoriasis Market in the US

  • 16.1. Market Size and Forecast

17. Systemic Lupus Erythematosus Market in the US

  • 17.1. Market Size and Forecast

18. Buying Criteria

19. Market Growth Drivers

20. Drivers and their Impact

21. Market Challenges

22. Impact of Drivers and Challenges

23. Market Trends

24. Trends and their Impact

25. Vendor Landscape

  • 25.1. Competitive Scenario
    • 25.1.1. Key News
    • 25.1.2. Mergers and Acquisitions
  • 25.2. Market Share Analysis 2014
    • 25.2.1. AbbVie
    • 25.2.2. Janssen Pharmaceuticals
    • 25.2.3. Biogen
    • 25.2.4. Amgen
    • 25.2.5. F. Hoffmann-La Roche
  • 25.3. Other and Future Prominent Vendors

26. Key Vendor Analysis

  • 26.1. AbbVie
    • 26.1.1. Key Facts
    • 26.1.2. Business Overview
    • 26.1.3. Product Segmentation by Revenue 2013
    • 26.1.4. Product Segmentation by Revenue 2012 and 2013
    • 26.1.5. Sales by Geography
    • 26.1.6. Business Strategy
    • 26.1.7. Key Developments
    • 26.1.8. SWOT Analysis
  • 26.2. Amgen
    • 26.2.1. Key Facts
    • 26.2.2. Business Overview
    • 26.2.3. Business Segmentation by Revenue 2013
    • 26.2.4. Product Portfolio by Revenue 2013
    • 26.2.5. Business Segmentation by Revenue 2012 and 2013
    • 26.2.6. Geographical Segmentation by Revenue 2013
    • 26.2.7. Business Strategy
    • 26.2.8. Recent Developments
    • 26.2.9. SWOT Analysis
  • 26.3. Biogen
    • 26.3.1. Key Facts
    • 26.3.2. Business Overview
    • 26.3.3. Business Segmentation by Revenue 2013
    • 26.3.4. Geographical Segmentation by Revenue 2013
    • 26.3.5. Business Strategy
    • 26.3.6. Key Developments
    • 26.3.7. SWOT Analysis
  • 26.4. F. Hoffmann-La Roche
    • 26.4.1. Key Facts
    • 26.4.2. Business Overview
    • 26.4.3. Business Segmentation
    • 26.4.4. Business Segmentation by Revenue 2012 and 2013
    • 26.4.5. Sales by Geography
    • 26.4.6. Business Strategy
    • 26.4.7. Key Information
    • 26.4.8. SWOT Analysis
  • 26.5. Janssen Pharmaceuticals
    • 26.5.1. Key Facts
    • 26.5.2. Business Overview
    • 26.5.3. Recent Developments
    • 26.5.4. SWOT Analysis

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Autoimmune Diseases Market in the US 2014-2019 (US$ million)
  • Exhibit 3: Segmentation of Autoimmune Diseases Market in the US by Type of Diseases
  • Exhibit 4: Percentage Share of Autoimmune Diseases Market Segment by Type of Disease 2014
  • Exhibit 5: Segmentation of Autoimmune Diseases Market in the US by Type of Molecules
  • Exhibit 6: Segmentation of Autoimmune Diseases Market in the US by Route of Administration
  • Exhibit 7: Ankylosing Spondylitis Market in the US 2014-2019 ($ millions)
  • Exhibit 8: Crohn's Disease Market in the US 2014-2019 ($ millions)
  • Exhibit 9: Multiple Sclerosis Market in the US 2014-2019 ($ millions)
  • Exhibit 10: Rheumatoid Arthritis Market in the US 2014-2019 ($ millions)
  • Exhibit 11: Psoriasis Market in the US 2014-2019 ($ millions)
  • Exhibit 12: Systemic Lupus Erythematosus Market in the US 2014-2019 ($ millions)
  • Exhibit 13: Autoimmune Diseases Market in the US 2014-2019 ($ millions)
  • Exhibit 14: AbbVie: Product Portfolio for Autoimmune Diseases
  • Exhibit 15: YoY Revenue of Humira in the US 2009-2014 ($ millions)
  • Exhibit 16: Janssen: Product Portfolio for Autoimmune Diseases
  • Exhibit 17: YoY Global Revenue of Remicade 2009-2014 ($ millions)
  • Exhibit 18: YoY Global Revenue of Simponi 2010-2014 ($ millions)
  • Exhibit 19: Biogen: Product Portfolio for Autoimmune Diseases
  • Exhibit 20: Biogen: Product Portfolio for Autoimmune Diseases
  • Exhibit 21: YoY Revenue of Tysabri in the US 2009-2014 ($ millions)
  • Exhibit 22: Revenue of Avonex in the US 2011-2014 ($ millions)
  • Exhibit 23: Region-wise Revenues of Plegridy 2014 ($ millions)
  • Exhibit 24: Region-wise Revenues of Tecfidera 2014 ($ millions)
  • Exhibit 25: Amgen: Product Portfolio for Autoimmune Diseases
  • Exhibit 26: Roche: Product Portfolio for Autoimmune Diseases
  • Exhibit 27: AbbVie Inc.: Product Segmentation by Revenue 2013
  • Exhibit 28: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 29: AbbVie Inc.: Sales by Geography 2013
  • Exhibit 30: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 31: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 32: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 33: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 34: Biogen: Business Segmentation by Revenue 2013
  • Exhibit 35: Biogen: Geographical Segmentation by Revenue 2013
  • Exhibit 36: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 37: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 38: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 39: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Back to Top